CHR to develop therapeutic clinical trial of liberation therapy for multiple sclerosis

Kondro, Wayne
September 2011
CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, pE793
Academic Journal
The article reports that the Canadian Institutes of Health Research (CIHR) plans to develop a Phase I/II interventional trial on the therapeutic validity of balloon venoplasty for multiple sclerosis (MS). It states that the trial seeks to ensure accurate and standardized identification of MS patients. It says that the trial would also assess the measures sensitive to venoplasty outcomes reported by patients.


Related Articles

  • Future MS care: a consensus statement of the MS in the 21st Century Steering Group. Rieckmann, Peter; Boyko, Alexey; Centonze, Diego; Coles, Alasdair; Elovaara, Irina; Havrdová, Eva; Hommes, Otto; LeLorier, Jacques; Morrow, Sarah; Oreja-Guevara, Celia; Rijke, Nick; Schippling, Sven // Journal of Neurology;Feb2013, Vol. 260 Issue 2, p462 

    The 'MS in the 21st Century' initiative was established with the purpose of (1) defining how multiple sclerosis (MS) treatment and standards of care should look in the 21st century; (2) developing a minimum standard of care across the world; and (3) motivating the broad MS community to align...

  • Atopic Dermatitis Diagnostic Criteria and Outcome Measures for Clinical Trials: Still a Mess. Flohr, Carsten // Journal of Investigative Dermatology;Mar2011, Vol. 131 Issue 3, p557 

    The past 2 decades have seen a heightened interest in atopic dermatitis-related research, leading to an exponential increase in publications. However, large numbers of diagnostic criteria and outcome measures hamper study comparability. The Harmonizing Outcome Measures for Eczema (HOME)...

  • Frankincense: systematic review. Ernst, E. // BMJ: British Medical Journal (International Edition);12/20/2008, Vol. 337 Issue 7684, p1439 

    Objective To assess evidence from randomised clinical trials about the effectiveness of extracts of Boswellia serrata (frankincense). Design Systematic review. Data sources Electronic searches on Medline, Embase, Cinahl, Amed, and Cochrane Library. Hand searches of conference proceedings,...

  • Dietary Supplement S-Adenosyl--Methionine (AdoMet) Effects on Plasma Homocysteine Levels in Healthy Human Subjects: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Thompson, Michael A.; Bauer, Brent A.; Loehrer, Laura L.; Cha, Stephen S.; Mandrekar, Jayawant N.; Sood, Amit; Wahner-Roedler, Dietlind L. // Journal of Alternative & Complementary Medicine;May2009, Vol. 15 Issue 5, p523 

    Objectives: To determine if exogenous S-adenosyl--methionine (AdoMet), a commonly used nutritional supplement, increases the level of plasma homocysteine (Hcy), a potential cardiovascular risk factor, in healthy human subjects. Design: Double-blind, placebo-controlled, randomized clinical trial....

  • Student-designed clinical trials: evaluating self-directed learning in pharmacology. Rangachari, P. K. // Naunyn-Schmiedeberg's Archives of Pharmacology;Jul2002, Vol. 366 Issue 1, p44 

    An evaluation exercise was developed for a third-year undergraduate problem-based course in pharmacology for science students. They were asked to design a clinical trial to evaluate a novel drug for an existing condition or an established drug for a novel condition. The exercise was assessed on...

  • Real-World EFFICACY. Horn, Susan D. // Drug Discovery & Development;May2007, Vol. 10 Issue 5, p30 

    The article discusses the importance of practice-based evidence for clinical practice improvement (PBE-CPI). The PBE-CPI methodology involves multivariable statistical analyses that contain extensive details on patient characteristics, standardized documentation of treatment details, and...

  • FDA's New Criteria Stress Single Measures, Documentation.  // JNCI: Journal of the National Cancer Institute;2/20/2008, Vol. 100 Issue 4, p235 

    The article reports on the new criteria set by the U.S. Food and Drug Administration (FDA) on how to incorporate patient-reported outcomes (PRO) in clinical trials. The new criteria focuses on five major points, which include the integration of the PRO protocol into the initial overall plan for...

  • Outcome Measures and Implications for Sample-Size Calculations. Zlowodzki, Michael; Bhandari, Mohit // Journal of Bone & Joint Surgery, American Volume;May2009 Supplement 3, Vol. 91-A, p35 

    This article focuses on items to consider when selecting outcome measures for a clinical study. The choice of outcome measures depends largely on the research question and the study design. Sample-size requirements can vary greatly, depending on the type and the number of outcome measures...

  • Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty? Freemantle, Nick; Calvert, Melanie; Wood, John; Eastaugh, Joanne; Griffin, Carl // JAMA: Journal of the American Medical Association;5/21/2003, Vol. 289 Issue 19, p2554 

    Composite outcomes, in which multiple end points are combined, are frequently used as primary outcome measures in randomized trials and are often associated with increased statistical efficiency. However, such measures may prove challenging for the interpretation of results. In this article, we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics